Lupus & antiphospholipid syndrome
iTRAQ-based mass spectrometry screen to identify serum biomarkers in systemic lupus erythematosus
Authors' conclusion
Since serum AMBP is validated to be elevated in SLE and correlated with renal disease
Study context
- Population
- Patients with systemic lupus erythematosus (SLE); validation in two cross-sectional cohorts, the second of different ethnic originsCohort I N=52
- Comparison
- SLE vs healthy controls
- Outcome
- Serum proteins identified by iTRAQ mass spectrometry and validated by ELISA
Methodological detailsiTRAQ-based mass spectrometry screen, ELISA validation in independent cross-sectional cohorts
- iTRAQ-based mass spectrometry screen
- ELISA validation in independent cross-sectional cohorts
Performance
As reported in the abstract
- Common proteins identified
- 85
- Proteins elevated (≥1.3) in SLE
- 16
- Proteins decreased (≤0.7) in SLE
- 23
- Serum AMBP, AZGP and RBP4 significantly elevated in inactive and active SLE vs healthy controls (HCs), Cohort I (fold change >2.5)
- p<0.05
- AUC of AMBP, AZGP and RBP4 for distinguishing active and inactive SLE from HCs
- 0.82-0.96
- Fold change of serum AMBP in active SLE vs HCs (largest); correlated with renal disease activity
- 5.96
Further findings
Serum AMBP correlation with serum creatinine, Cohort II
- Correlation (r) of serum AMBP with serum creatinine; elevation validated
- r=0.60, p<0.001
Original publication
iTRAQ-based mass spectrometry screen to identify serum biomarkers in systemic lupus erythematosus. Lupus Sci Med. Published 23 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →